Merck & Co's drug Keytruda, the first in a new wave of immune-boosting medicines to be approved for treating melanomas in the United States, also has potential in stomach cancer, new research shows. Early clinical trial results reported on Sunday mean that gastric, or stomach cancer can be added to a growing list of tumor types where so-called immunotherapy may have an important role to play.